Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smartwatch-Guided heart drug study aims to cut ER visits for AFib patients

NCT ID NCT07445789

First seen Mar 06, 2026 · Last updated May 22, 2026 · Updated 13 times

Summary

This study tests two common heart rate-lowering drugs, verapamil and metoprolol, in 436 adults with paroxysmal atrial fibrillation (AF), a condition causing irregular heartbeats. Some participants will also use a smartwatch to track their heart rhythm and guide self-care. The goal is to see which approach better controls heart rate and reduces hospital visits, cardioversions, and ablation procedures.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.